Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:hospital
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:lidocaine
gptkb:lidocaine_hydrochloride |
| gptkbp:activities |
blocks sodium channels
|
| gptkbp:approves |
gptkb:Europe
gptkb:Australia gptkb:FDA gptkb:Native_American_tribe |
| gptkbp:aroma |
0.5%
0.2% |
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:duration |
3 to 8 hours
|
| gptkbp:formulation |
gptkb:software_framework
liposomal |
| https://www.w3.org/2000/01/rdf-schema#label |
ropivacaine
|
| gptkbp:ingredients |
C17 H26 N2 O2
|
| gptkbp:is_used_for |
pain management
|
| gptkbp:manager |
injection
|
| gptkbp:related_to |
gptkb:bupivacaine
|
| gptkbp:side_effect |
dizziness
headache nausea allergic reaction hypotension |
| gptkbp:traded_on |
Naropin
|